Tryptophan levels may explain why some migraine drugs fail
NCT ID NCT07177885
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at why over 20% of migraine patients don't respond well to triptans, a common migraine medication. Researchers will compare tryptophan and related substances in the blood of 144 people who either respond or don't respond to triptans. The goal is to understand the biological reasons behind treatment failure, which could lead to better personalized migraine care in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors personalize migraine treatments based on a patient's tryptophan levels.
- What could go wrong
- This is an observational study, not a treatment trial. It may not lead to any immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Clermont-Ferrand
RECRUITINGClermont-Ferrand, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a numbing nose treatment stop migraine pain in its tracks?
- Can migraine meds be safe while breastfeeding? a new study investigates
- Could a symptom registry unmask hidden migraine variants?
- A migraine-blocking antibody tested in children as young as 6
- Mind over migraine: brain network may explain why some expect side effects
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?